Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05659927 | Active, not recruiting | Asthma

Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects
Sponsor:

Shanghai Mabgeek Biotech.Co.Ltd

Brief Summary:

To determine the safety and tolerability of MG-ZG122 in Chinese healthy adult subjects

Condition or disease

Asthma

Intervention/treatment

MG-ZG122 Humanized Monoclonal Antibody Injection

Placebo

Phase

Phase 1

Detailed Description:

Main purpose: To determine the safety and tolerability of MG-ZG122 humanized monoclonal antibody injection (MG-ZG122 for short) in Chinese healthy adult subjects. Secondary objective: To study the pharmacokinetic (PK) characteristics of MG-ZG122 in healthy Chinese adult volunteers, and to provide a basis for the design of clinical trial protocols for subsequent clinical trials; To evaluate the immunogenicity of MG-ZG122 in Chinese healthy adult volunteers; Preliminary exploration of the efficacy of MG-ZG122 in Chinese healthy adult subjects Impact of Biomarkers in Physiology (PD).}}

Study Type : Interventional
Estimated Enrollment : 34 participants
Masking : Quadruple
Primary Purpose : Treatment
Official Title : Safety, Tolerability, and Pharmacokinetics of MG-ZG122 in a Single Subcutaneous Injection in Chinese Healthy Adult Subjects: a Single-center, Randomized, Double-blind, Placebo-controlled, Dose-increasing Phase I Clinical Trial
Actual Study Start Date : February 9, 2023
Estimated Primary Completion Date : January 26, 2024
Estimated Study Completion Date : March 23, 2024
Arm Intervention/treatment

Experimental: MG-ZG122 first dose group

4 cases in the 52.5 mg dose group (2 cases of placebo, 2 cases of experimental drug)

Drug: MG-ZG122 Humanized Monoclonal Antibody Injection

Drug: Placebo

Experimental: MG-ZG122 second dose group

10 cases in the 105 mg dose group (2 cases of placebo, 8 cases of experimental drug)

Drug: MG-ZG122 Humanized Monoclonal Antibody Injection

Drug: Placebo

Experimental: MG-ZG122 third dose group

10 cases in the 210 mg dose group (2 cases of placebo, 8 cases of experimental drug)

Drug: MG-ZG122 Humanized Monoclonal Antibody Injection

Drug: Placebo

Experimental: MG-ZG122 forth dose group

10 cases in the 420 mg dose group (2 cases of placebo, 8 cases of experimental drug)

Drug: MG-ZG122 Humanized Monoclonal Antibody Injection

Drug: Placebo
Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Accepts Healthy Volunteers
Criteria
Inclusion Criteria
  • - 1. The subjects signed the ICF before the study and fully understood the research content, process and possible adverse reactions; voluntarily participated in the study and were able to complete the study according to the program requirements.
  • 2. Chinese healthy adult subjects aged 18-65 years (including the boundary value) , both male and female; 3. Male volunteers weighing ≥50 kg; women weighing ≥40 kg; body mass index (BMI) within the range of 19.0-26.0 kg/m2 (including boundary values; BMI=weight kg/height 2 m2);
Exclusion Criteria
  • Patients with acute or subacute infection (such as fever, cough, urgency, dysuria, abdominal pain, diarrhea and skin infection wounds, etc.) within 2 weeks before screening, or acute or chronic infection within 4 weeks before screening history, and receiving systemic anti-infective treatment;
  • Those who have a history of tuberculosis infection in the past;
  • The results of physical examination, vital sign measurement, laboratory examination, electrocardiogram, chest X-ray, etc. are abnormal and have clinical significance;
  • Those who are known to be allergic to monoclonal antibody drugs or excipients of MG-ZG122 injection, or food allergies judged by the investigator to be unsuitable to participate in the researcher;
  • Those who have been vaccinated within 1 month before screening or plan to be vaccinated during the study;
  • Those who have used any prescription drugs within 2 weeks before administration, those who have used non-prescription drugs or traditional Chinese medicines within 1 week before administration, or those who are expected to use prescription drugs, non-prescription drugs and traditional Chinese medicines during the study period;
  • Those who have received any research non-biological agents within 5 half-lives (if known) or within 3 months (whichever is longer) before administration, or have participated in other clinical trials or plan to participate in other clinical trials during the study period. clinical trial subjects;
  • Those who have special requirements for diet or cannot accept a unified diet;
  • Women who are lactating and pregnant, or female volunteers of childbearing age have a positive serum pregnancy test;
Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects

Location Details

Please Choose a site

Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

China, Anhui

The Second Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China, 230601